You are here: Industry Insights > HBV

News List

Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study prnasia
December 04, 2020
Ascletis Pharma Inc. announces today that Phase IIa data demonstrated that ASC22 (Envafolimab) is safe and well tolerated in chronic hepatitis B (CHB) patients and Phase IIb clinical trial has been initiated. ASC22 (Envafolimab) is a first-in-class ...
Extension Study of Vebicorvir for Chronic HBV Does Not Achieve Meaningful SVR Rates americanpharmaceuticalreview
November 16, 2020
Assembly Biosciences provided an update on the ongoing open-label Phase 2 extension study (Study 211) of vebicorvir (VBR, or ABI-H0731) in patients with chronic HBV infection. Study 211 is exploring whether sustained virologic response (SVR) could be ...
First HBV patient dosed in phase IIa clinical trial of ASC22 pharmaceutical-business-review
August 19, 2020
Ascletis Pharma announces the dosing of the first HBV patient in Phase IIa clinical trial of ASC22, which is a first-in-class, subcutaneously administered PD-L1 antibody.
Assembly Biosciences Announces FDA Fast Track Designation for Chronic Hepatitis B Virus Treatment americanpharmaceuticalreview
July 21, 2020
Assembly Biosciences announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABI-H2158 (2158) for the treatment of patients with chronic HBV infection.
Vaccitech begins Phase 1 clinical study of VTP-300 immunotherapeutic to treat chronic Hepatitis B expresspharma
June 24, 2020
Once the VTP-300 prime dose is confirmed, Vaccitech plans to initiate a Phase 1b/2a study, HBV002, in Q3 2020.
Cytovance and Akshaya Enter Vaccine Collaboration contractpharma
April 26, 2020
Partnership to focus on therapeutics for treatment of coronavirus and hepatitis B virus infections.
Spring Bank Stops Dosing of Inarigivir Patients americanpharmaceuticalreview
January 02, 2020
Spring Bank Pharmaceuticals announced the company has stopped dosing and enrolling patients in its Phase 2b CATALYST trials ...
USPSTF Reaffirms Benefit of Hep B Screening in Pregnant Women drugs
July 24, 2019
The U.S. Preventive Services Task Force (USPSTF) recommends screening pregnant women for hepatitis B virus (HBV) infection at their first prenatal visit (A recommendation).
CDC: Proportion of Increased-Risk Deceased Organ Donors on Rise drugs
January 25, 2019
Among deceased organ donors, there has been an increase in the proportion at increased risk for transmitting hepatitis B virus (HBV).....
Many New Cancer Patients Unaware of Their Hepatitis Status drugs
January 23, 2019
A substantial proportion of patients with newly diagnosed cancer and concurrent hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are unaware of their viral infection at the time of cancer diagnosis...

Previous page 1 2 3 Next page